arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

RIGEL PHARMACEUTICALS INC

RIGL
$40.12 ▲ +0.97 (+2.49%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

RIGEL PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $738.7M
Dividend Yield
Revenue Growth 10.3%
Op. Margin 20.2%
ROIC 2.0%
FCF / Share $0.15
Trailing P/E 85.4x
Price / Book 1.9x
FCF Yield 0.4%
Debt / Equity 0.11
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$58.82M
↑ +10.3%
Net Income Profit after all expenses
$8.65M
↓ -24.4%
Operating Margin Operating profit as % of sales
20.2%
↓ -39.1% 95th
FCF / Share Free cash flow per share
$0.15
↓ -88.9%
Long-Term Debt Long-term obligations
$45.00M
↓ -14.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
92
Returns
99
Financial Health
83
Cash Quality
29

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters